title: Tanezumab in the treatment of chronic musculoskeletal conditions.
abstract: The management of pain associated with chronic musculoskeletal conditions represents a significant challenge for the clinician. There remains a need for novel medications that have a significant analgesic benefit and are also safe and well tolerated. Both pre-clinical and clinical data have provided evidence of the role of nerve growth factor (NGF) in a multitude of pain eliciting conditions. Therefore, the development of monoclonal antibodies to NGF for chronic painful musculoskeletal conditions has generated interest. Areas covered: This manuscript is a review that examines both the pharmacological properties and clinical studies of tanezumab, the most widely studied antibody to NGF, for management of osteoarthritis (OA) and low back pain. In addition, the safety and tolerability profile and development history of tanezumab are also discussed. Expert opinion: Most studies provide strong support for the ability of tanezumab to provide clinically meaningful pain relief in individuals with these conditions, with longer-term studies suggesting durability of effect. The adverse event profile appears favorable, assuming the risk mitigation strategies are effective at reducing the incidence of joint-related side effects. Further data are being collected to define the optimal dose and dosing strategy in both OA and chronic low back pain.
authors.affiliation: a Rehabilitation Institute of Chicago , Chicago , IL , USA.|b Department of Physical Medicine and Rehabilitation , Northwestern University Feinberg School of Medicine , Chicago , IL , USA.
authors.forename: Prakash
authors.initials: P
authors.lastname: Jayabalan
authors.affiliation: b Department of Physical Medicine and Rehabilitation , Northwestern University Feinberg School of Medicine , Chicago , IL , USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Schnitzer
mesh_terms: D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D017116:Low Back Pain / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D009140:Musculoskeletal Diseases / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism*; D020932:Nerve Growth Factor / Q000276:immunology / Q000378:metabolism; D010003:Osteoarthritis / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D010147:Pain Measurement / Q000187:drug effects / Q000379:methods; D020800:Receptor, Nerve Growth Factor / Q000276:immunology / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D000700:Analgesics; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C502240:NGF protein, human; D020800:Receptor, Nerve Growth Factor; D020932:Nerve Growth Factor; C549319:tanezumab
keywords: Tanezumab; anti-NGF; low back pain; nerve growth factor; osteoarthritis